Azithromycin alters macrophage phenotype

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 554-560

  Murphy, Brian S ^a   Sundareshan, Vidya ^a   Cory, Theodore J ^a   Hayes Jr , Don ^a   Anstead, Michael I ^a   Feola, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cystic fibrosis; Inflammation; Macrolides

Indexed keywords

ARGINASE; AZITHROMYCIN; CD23 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MANNOSE RECEPTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL POLARITY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; IMMUNE RESPONSE; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; AZITHROMYCIN; CELL LINE; CELL LINE, TRANSFORMED; CYTOKINES; IMMUNOPHENOTYPING; MACROPHAGES; MICE; MICE, INBRED BALB C;

EID: 40049104684     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn007     Document Type: Article

References (50)

1. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003; 290 1749.
2. Equi A, Balfour-Lyrin IA, Bush A et al. Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled cross-over trial. Lancet 2002; 360: 978-84.
3. Wolter J, Seeney S, Bell S et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax 2002; 57: 212.
4. Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41 Suppl B: 47-50.
5. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41-50S.
6. Mizukane R, Hirakata Y, Kaku M et al. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38: 528-33.
7. Molinari G, Guzman CA, Pesce A et al. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31: 681-8.
8. /- mice. Antimicrob Agents Chemother 2007; 51: 3677-87.
9. Ianaro A, Ialenti A, Maffia P et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63.
10. Levert H, Gressier B, Moutard I et al. Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation 1998; 22: 191-201.
11. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62-9S; quiz 69S.
12. Yasuda H, Ajiki Y, Koga T et al. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 1993; 37; 1749-55.
13. Ichimiya T, Takeoka K, Hiramatsu K et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186-91.
14. Yanagihara K, Tomono K, Imamura Y et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337-42.
15. Joseph T, Look D, Ferkol T. NF-κB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2005; 288: L471-9.
16. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;23-5.
17. Dalton DK, Pitts-Meek S, Keshav S et al. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259: 1739-42.
18. Stout RD, Suttles J. Functional plasticity of macrophages: Reversible adaptation to changing microenvironments. J Leukoc Biol 2004; 76: 509-13.
19. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. Eur J Cancer 2004; 40: 1660-7.
20. Nelms K, Keegan AD, Zamorano J et al. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17 701-38.
21. Montaner LJ, da Silva RP, Sun J et al. Type 1 and type 2 cytokine regulation of macrophage endocytosis: Differential activation by IL-4/ IL-13 as opposed to IFN-γ or IL-10. J Immunol 1999; 162: 4606-13.
22. Song E, Ouyange N, Horbelt M et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000; 204: 19-28.
23. Edwards JP, Zhang X, Frauwirth KA et al. Biochemical and functional characterization of three-activated macrophage populations. J Leukoc Biol 2006; 80: 1298-307.
24. Ralph P, Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature 1975; 257: 393-4.
25. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized. M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
26. Stein M, Keshav S, Harris N et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
27. Becker S, Daniel ED. Antagonistic and additive effects of IL-4 and interferon-γ on human monocytes and macrophages: Effects on Fc receptors HLA-D antigens, and superoxide production. Cell Immunol 1990; 129: 351-62.
28. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198-201.
29. Cook EB, Stahl JL, Lowe L et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry; allergics vs. non-allergics. J Immunol Methods 2001; 254: 109-18.
30. Chen R, Lowe L, Wilson JD et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 1999; 45: 1693-4.
31. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998; 160: 5347-54.
32. Munder M, Eichmann K, Moran JM et al. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999; 163: 3771-7.
33. Cipolli M, Cazzola G, Novelli A et al. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001; 21: 353-60.
34. Seral C, Michot JM, Chanteux H et al. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob Agents Chemother 2003; 47: 1047-51.
35. Doyle AG, Herbein F, Montaner LJ et al. Interleukin-13 alters the activation state of murine macrophages in vitro: Comparison with interleukin-4 and interferon-γ. Eur J Immunol 1994; 24: 1441-5.
36. Doherty TM, Kastelein R, Menon S et al. Modulation of murine macrophage function by IL-13. J Immunol 1993; 151: 7151-60.
37. Kambayashi T, Jacob CO, Strassmann G. IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mono-nuclear phagocytes. Cell Immunol 1996; 171: 153-8.
38. Hartl D, Griese M, Kappler M et al. Pulmonary TH2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-11.
39. Hesse M, Modolell M, La Flamme AC et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: Granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001; 167: 6533-44.
40. Grasemann H, Schwiertz R, Matthiesen S et al. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005; 172: 1523-8.
41. Prasse A, Pechkovsky DV, Toews GB et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173: 781-92.
42. Hodge S, Hodge G, Brozyna S et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28: 486-95.
43. Moser C, Jensen PO, Kobayashi O et al. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 2002; 127: 206-13.
44. Brazova J, Sediva A, Pospisilova D et al. Differential cytokine profile in children with cystic fibrosis. Clin Immunol 2005; 115: 210-5.
45. Moser C, Kjaergaard S, Pressler T et al. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 2000; 108: 329-35.
46. Telford G, Wheeler D, Williams P et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-1-homoserine lactone has immunomodulatory activity. Infect Immun 1998; 66: 36-42.
47. Bonfield TL, Panuska JR, Konstan MW et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152 2111-8.
48. Bonfield TL, Konstan MW, Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 1999; 104: 72-8.
49. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 911-5.
50. Muhlebach MS, Stewart PW, Leigh MW et al. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160: 186-91.